{
    "name": "interferon alfa n3",
    "comment": "Rx",
    "other_names": [
        "Alferon N"
    ],
    "classes": [
        "Immunomodulators"
    ],
    "source": "https://reference.medscape.com/drug/alferon-n-interferon-alfa-n3-343183",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: not known whether excreted in breast milk, do not nurse or do not initiate treatment"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known whether excreted in breast milk, do not nurse or do not initiate treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to human interferon alpha proteins, mouse IgG, egg proteins, or neomycin"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in cardiovascular disease, severe pulmonary disease, diabetes mellitus with ketoacidosis, coagulopathies, severe myelosuppression, seizure disorder",
                "Discontinue immediately if anaphylactic reactions develop",
                "Safety/efficacy of repeat course not established",
                "Theoretical remote possibility of pathogen transmission from albumin present in the solution",
                "Do not change brands of interferon"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "interferon alfa n3, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "interferon alfa n3, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "interferon alfa n3, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "interferon alfa n3, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "interferon alfa n3, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "interferon alfa n3, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "interferon alfa n3 increases toxicity of aldesleukin by pharmacodynamic synergism. Use Caution/Monitor. Interferon (alfa) may enhance adverse effects which can include risk of myocardial and renal toxicity with concomitant use. Advisable to consider alternative therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "interferon alfa n3 and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, interferon alfa n3.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod, interferon alfa n3.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and interferon alfa n3 both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "interferon alfa n3 increases levels of theophylline by decreasing metabolism. Use Caution/Monitor. Greater risk of interaction in smokers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and interferon alfa n3 both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "interferon alfa n3 increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "interferon alfa n3 increases levels of zidovudine by decreasing metabolism. Use Caution/Monitor. Interferons may enhance potential for adverse effects. Patients should be monitored for signs and symptoms of increased myelosuppression and liver decompensation."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Myalgia",
            "percent": "45"
        },
        {
            "name": "Fever",
            "percent": "40"
        },
        {
            "name": "Headache",
            "percent": "31"
        },
        {
            "name": "Chills",
            "percent": "14"
        },
        {
            "name": "Fatigue",
            "percent": "14"
        },
        {
            "name": "Decreased WBC",
            "percent": "9"
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Taste disturbance",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "Nose bleed",
            "percent": null
        },
        {
            "name": "Groin and lymph node swelling",
            "percent": null
        },
        {
            "name": "Pharyngitis",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Visual disturbance",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Thirst",
            "percent": null
        }
    ]
}